Researchers at the University of Texas Medical Branch recently confirmed the presence of neutralizing antibodies to SARS-CoV-2 in a common subcutaneous antibody therapy (Hizentra) used to treat immunocompromised or immunodeficient patients, citing its protective benefits to the immunocompromised patient community. The findings were recently published in the Journal of Allergy and Clinical Immunology.
New study shows common antibody therapy has anti-SARS-CoV-2 antibodies
Researchers at the University of Texas Medical Branch recently confirmed the presence of neutralizing antibodies to SARS-CoV-2 in a common subcutaneous antibody therapy (Hizentra) used to treat immunocompromised or immunodeficient patients, citing its protective benefits to the immunocompromised patient community. The findings were recently published in the Journal of Allergy and Clinical Immunology.